Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
AssigneeCorning Incorporated
InventorsWendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
Life of this patent
Estimating the term…
Abstract
The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, PROCRIT (epoetin alfa), REMICADE (Infliximab) or DORIBAX (doripenem).
Claims21
A pharmaceutical composition comprising:
- an active pharmaceutical ingredient selected from the group consisting of epoetin alfa, doripenem monohydrate, infliximab, an erythropoiesis-stimulating glycoprotein, and an antibody specific for human necrosis factor alpha;
- and
- a pharmaceutically acceptable excipient;
- wherein the pharmaceutical composition is contained within a delamination resistant glass container such that the pharmaceutical composition has increased stability, product integrity, or efficacy.
A method of enhancing the stability, product integrity, or efficacy of a pharmaceutical composition comprising an active pharmaceutical ingredient selected from the group consisting of epoetin alfa, doripenem monohydrate, infliximab, an erythropoiesis-stimulating glycoprotein, and an antibody specific for human necrosis factor alpha, wherein the method comprises containing the pharmaceutical composition in a delamination resistant glass container.
Dependencies are inferred from the claim text.